RxDoctor Payments Data

Steven Anderson, MD

Ophthalmology · Ames, IANPI 1942288717

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.7%), ownership interests and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Alcon at 50.4% of the total.

$4,852in general payments, 2019–2025

Across 65 payments — averaging $74.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • US Retina LLC$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$118
  • AbbVie$89
  • Bausch & Lomb Americas Inc.$84
  • Sight Sciences, Inc.$40
  • plus $72 from 3 others

What the payments were for

  • Travel & lodging$77716%
  • Food & beverage$2,07043%
  • Ownership interest$2,00441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,852 in reported general payments places this provider in the 80th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$903,857
Medicare patients
1,797
Services billed
7,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate1,594$79,128
MoxifloxacinMoxifloxacin Hcl1,532$32,955
LumiganBimatoprost42$21,261
RestasisCyclosporine13$13,102
ProlensaBromfenac Sodium30$10,146
RhopressaNetarsudil Mesylate16$5,659
Latanoprost513$3,482
Brimonidine Tartrate54$2,533
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat108$1,189
Timolol Maleate118$1,163
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,114
Dorzolamide Hcl24$329
Acyclovir12$287
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim24$153
Tobramycin15$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$89$34,36355 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$118$10,14630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 172 ophthalmology providers in Iowa.

Other ophthalmology in Ames

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →